Welcome to our dedicated page for Tabula Rasa Heal news (Ticker: TRHC), a resource for investors and traders seeking the latest updates and insights on Tabula Rasa Heal stock.
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) provides investors and healthcare professionals with essential updates through this centralized news resource. As a leader in value-based care solutions, TRHC specializes in medication risk management and technology-driven healthcare optimization for at-risk populations.
This page aggregates official announcements including strategic partnerships, financial disclosures, and operational developments. Users will find updates on TRHC's pending merger with ExactCare Pharmacy under Nautic Partners, clinical program expansions, and innovations in personalized medication management systems.
Key content categories include earnings reports, merger/acquisition details, regulatory filings, and partnership announcements with PACE programs. All information is sourced directly from company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to TRHC's latest developments in healthcare technology and pharmacy services. For historical data and investor materials, visit the company's Investor Relations portal through their official website.
Tabula Rasa HealthCare (TRHC) has scheduled a conference call and webcast for May 9, 2023, at 8:30 a.m. EDT to discuss its first quarter 2023 financial results. The financial results will be released after market close on May 8, 2023. TRHC focuses on medication safety solutions, utilizing proprietary technology like MedWise® to optimize medication regimens, minimize adverse drug events, and reduce healthcare costs. Their clinical tele-pharmacy network enhances patient care nationwide, and their services are trusted by health plans and at-risk provider groups for value-based care initiatives.
Tabula Rasa HealthCare (TRHC) has appointed Brian Adams as President and Chief Executive Officer, effective immediately. Adams, who was previously interim CEO, will also join the Board of Directors. Richard W. Rew II has been named Chief Legal Officer and Corporate Secretary, effective April 10, 2023. The company announced preliminary unaudited revenue for Q1 2023, expected to be between $87.0 million and $88.5 million, exceeding prior guidance of $82 million to $84 million. The company plans to report full financial results in early May. The new leadership aims to advance solutions for the Program of All-Inclusive Care for the Elderly (PACE) market and improve patient care.
Tabula Rasa HealthCare (TRHC) reported a strong fourth quarter for 2022, achieving $82.7 million in revenue, a 20% increase year-over-year. Despite this growth, the company recorded a GAAP net loss of $18.4 million, up from $13.0 million the previous year. Full-year revenue reached $299.5 million, a 15% increase, but the net loss grew to $77.3 million. The company has made strategic moves, including leadership changes and the divestiture of non-core businesses, to focus on sustainable growth. Looking ahead, TRHC projects revenue for 2023 to be between $343 million and $354 million, with adjusted EBITDA guidance of $17 million to $20 million.
Cureatr has acquired SinfoníaRx from Tabula Rasa HealthCare (NASDAQ: TRHC), enhancing its medication therapy management (MTM) services. This acquisition is expected to strengthen Cureatr's clinical pharmacy offerings and expand its team, improving medication management for health plans and patients nationwide. The integration aims to reduce healthcare costs and enhance patient experience through innovative programs. Cureatr's existing platform, Meds 360°, will leverage SinfoníaRx's technology and expertise to address the $528 billion medication management issue in the U.S. The acquisition aligns with Cureatr's mission to provide essential clinical pharmacist services to patients.
